A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT

Clinical trial NCT03190733 · UNKNOWN

Trial details

NCT number: NCT03190733
Sponsor: Zhujiang Hospital
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

Chronic Graft-versus-host-disease Leukemia Relapse

Start date: 2017-08-30
Primary completion: 2020-09-30
Enrollment: 192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.